Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

388
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
388
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

394
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
394
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

381
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
381

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Citrullinated Histone 3 as a Marker of NETosis at Opposite Ends of Hemostasis: Evidence From Thrombosis-Prone MPN and Bleeding-Prone Hemophilia.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

National Perspectives on Academic CAR-T Cell Therapy in Türkiye: A report from Turkish Society of Hematology, Scientific Subcommittee on Cell and Gene Therapies (TSH-CGT SSC).

Turkish journal of haematology : official journal of Turkish Society of Haematology·2026
Same author

Seventh Åland Island Meeting on von Willebrand Disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Evaluation of hepatitis B virus screening and reactivation in patients with hematological malignancies receiving rituximab-based chemoimmunotherapy: A single-center retrospective study.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Von Willebrand disease.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Assay discrepancy in mild haemophilia A.

European journal of haematology. Supplementum·2014
Same journal

On-demand treatment in persons with severe haemophilia.

European journal of haematology. Supplementum·2014
Same journal

Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature review.

European journal of haematology. Supplementum·2014
Same journal

Perinatal aspects of haemophilia.

European journal of haematology. Supplementum·2014
Same journal

Outcome measures in haemophilia: a systematic review.

European journal of haematology. Supplementum·2014
Same journal

Introduction. Outcome measures in haemophilia: a systematic review.

European journal of haematology. Supplementum·2014
See all related articles

Related Experiment Video

Updated: Apr 27, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K

Methods for individualising factor VIII dosing in prophylaxis.

Muhlis Cem Ar1, Ines Vaide, Erik Berntorp

  • 1Department of Haematology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey.

European Journal of Haematology. Supplementum
|June 25, 2014
PubMed
Summary
This summary is machine-generated.

Individualizing factor VIII (FVIII) prophylaxis for severe haemophilia A is recommended. Tailoring FVIII doses based on individual patient needs improves treatment outcomes and resource allocation.

Keywords:
haemophiliapharmacokineticsprophylaxistreatment tailoring

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

30.2K

Related Experiment Videos

Last Updated: Apr 27, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

30.2K

Area of Science:

  • Hematology
  • Genetics
  • Pharmacology

Background:

  • Haemophilia A is a genetic bleeding disorder caused by factor VIII deficiency.
  • Recurrent bleeds lead to haemophilic arthropathy and disability without treatment.
  • Prophylaxis aims to prevent or slow joint damage.

Purpose of the Study:

  • To review literature on individualizing factor VIII prophylaxis in severe haemophilia A.
  • To highlight the need for tailored FVIII dosing strategies.

Main Methods:

  • Systematic literature search of PubMed for relevant articles.
  • Focus on studies detailing individualization of FVIII prophylaxis.

Main Results:

  • Standard prophylactic regimens may not suit all severe haemophilia A patients.
  • Individual factors (age, joint status, pharmacokinetics) necessitate dose variation.
  • Dose tailoring by clinical outcome, first described in 1994, is now recommended.

Conclusions:

  • Individualizing FVIII prophylaxis is crucial for effective haemophilia A management.
  • Tailored dosing improves patient outcomes and optimizes factor concentrate distribution.
  • Countries should implement policies for individualized prophylaxis.